In breast cancers, immunotherapy is being tested in combination with antiproliferative HER-2 inhibitors (66) or DNA repair inhibitors such as PARP (poly ADP-ribose polymerase 1) inhibitors (67) to increase the mutational burden of tumors and make them better targets for the immune system. This evidence concerns the gene ERBB2 and breast cancer.